TRMED Intrinsic Valuation and Fundamental Analysis - Thor Medical ASA - Alpha Spread
T

Thor Medical ASA
OSE:TRMED

Watchlist Manager
Thor Medical ASA
OSE:TRMED
Watchlist
Price: 1.01 NOK 3.06% Market Closed
Market Cap: 237.2m NOK
Have any thoughts about
Thor Medical ASA?
Write Note

Intrinsic Value

TRMED's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one TRMED stock under the Base Case scenario is 0.03 NOK. Compared to the current market price of 1.01 NOK, Thor Medical ASA is Overvalued by 97%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TRMED Intrinsic Value
0.03 NOK
Overvaluation 97%
Intrinsic Value
Price
T
Worst Case
Base Case
Best Case

Valuation Backtest
Thor Medical ASA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TRMED cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TRMED?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Thor Medical ASA

Provide an overview of the primary business activities
of Thor Medical ASA.

What unique competitive advantages
does Thor Medical ASA hold over its rivals?

What risks and challenges
does Thor Medical ASA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Thor Medical ASA.

Provide P/S
for Thor Medical ASA.

Provide P/E
for Thor Medical ASA.

Provide P/OCF
for Thor Medical ASA.

Provide P/FCFE
for Thor Medical ASA.

Provide P/B
for Thor Medical ASA.

Provide EV/S
for Thor Medical ASA.

Provide EV/GP
for Thor Medical ASA.

Provide EV/EBITDA
for Thor Medical ASA.

Provide EV/EBIT
for Thor Medical ASA.

Provide EV/OCF
for Thor Medical ASA.

Provide EV/FCFF
for Thor Medical ASA.

Provide EV/IC
for Thor Medical ASA.

What are the Revenue projections
for Thor Medical ASA?

How accurate were the past Revenue estimates
for Thor Medical ASA?

What are the Net Income projections
for Thor Medical ASA?

How accurate were the past Net Income estimates
for Thor Medical ASA?

What are the EPS projections
for Thor Medical ASA?

How accurate were the past EPS estimates
for Thor Medical ASA?

What are the EBIT projections
for Thor Medical ASA?

How accurate were the past EBIT estimates
for Thor Medical ASA?

Compare the revenue forecasts
for Thor Medical ASA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Thor Medical ASA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Thor Medical ASA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Thor Medical ASA compared to its peers.

Compare the P/E ratios
of Thor Medical ASA against its peers.

Discuss the investment returns and shareholder value creation
comparing Thor Medical ASA with its peers.

Analyze the financial leverage
of Thor Medical ASA compared to its main competitors.

Show all profitability ratios
for Thor Medical ASA.

Provide ROE
for Thor Medical ASA.

Provide ROA
for Thor Medical ASA.

Provide ROIC
for Thor Medical ASA.

Provide ROCE
for Thor Medical ASA.

Provide Gross Margin
for Thor Medical ASA.

Provide Operating Margin
for Thor Medical ASA.

Provide Net Margin
for Thor Medical ASA.

Provide FCF Margin
for Thor Medical ASA.

Show all solvency ratios
for Thor Medical ASA.

Provide D/E Ratio
for Thor Medical ASA.

Provide D/A Ratio
for Thor Medical ASA.

Provide Interest Coverage Ratio
for Thor Medical ASA.

Provide Altman Z-Score Ratio
for Thor Medical ASA.

Provide Quick Ratio
for Thor Medical ASA.

Provide Current Ratio
for Thor Medical ASA.

Provide Cash Ratio
for Thor Medical ASA.

What is the historical Revenue growth
over the last 5 years for Thor Medical ASA?

What is the historical Net Income growth
over the last 5 years for Thor Medical ASA?

What is the current Free Cash Flow
of Thor Medical ASA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Thor Medical ASA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Thor Medical ASA

Current Assets 45.3m
Cash & Short-Term Investments 41.8m
Receivables 3.6m
Other Current Assets -33k
Non-Current Assets 285.5m
PP&E 1m
Intangibles 284.5m
Current Liabilities 4.4m
Accounts Payable 2.1m
Other Current Liabilities 2.3m
Non-Current Liabilities 54.5m
Other Non-Current Liabilities 54.5m
Efficiency

Earnings Waterfall
Thor Medical ASA

Revenue
800k NOK
Operating Expenses
-35.8m NOK
Operating Income
-35m NOK
Other Expenses
-17.2m NOK
Net Income
-52.2m NOK

Free Cash Flow Analysis
Thor Medical ASA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TRMED Profitability Score
Profitability Due Diligence

Thor Medical ASA's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

29/100
Profitability
Score

Thor Medical ASA's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

TRMED Solvency Score
Solvency Due Diligence

Thor Medical ASA's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
High Altman Z-Score
74/100
Solvency
Score

Thor Medical ASA's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TRMED Price Targets Summary
Thor Medical ASA

There are no price targets for TRMED.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TRMED?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for TRMED is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about TRMED dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

TRMED Price
Thor Medical ASA

1M 1M
-3%
6M 6M
+9%
1Y 1Y
-18%
3Y 3Y
-96%
5Y 5Y
-97%
10Y 10Y
-97%
Annual Price Range
1.01
52w Low
0.884
52w High
1.646
Price Metrics
Average Annual Return -21.75%
Standard Deviation of Annual Returns 65.19%
Max Drawdown -98%
Shares Statistics
Market Capitalization 235.9m NOK
Shares Outstanding 234 859 000
Percentage of Shares Shorted
N/A

Competitive Landscape

Profile

Thor Medical ASA

Country

Norway

Industry

Biotechnology

Market Cap

235.9m NOK

Dividend Yield

0%

Description

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 16 full-time employees. The company went IPO on 2014-07-07. The firm is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The firm is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

Contact

OSLO
Oslo
Kjelsasveien 168 B
+4722183301
www.nordicnanovector.com

IPO

2014-07-07

Employees

16

Officers

See Also

Discover More
What is the Intrinsic Value of one TRMED stock?

The intrinsic value of one TRMED stock under the Base Case scenario is 0.03 NOK.

Is TRMED stock undervalued or overvalued?

Compared to the current market price of 1.01 NOK, Thor Medical ASA is Overvalued by 97%.

Back to Top